free web stats

Law Offices of Thomas J. Lamb

Retinal Detachments With Avelox Use Cannot Be Ruled Out: Health Canada

By

We have previously written several articles on our Drug Injury Watch site (http://www.drug-injury.com) about serious vision problems and visual side effects associated with Avelox, Levaquin, and Cipro during the past several years, as seen below:

  • Levaquin / Cipro / Avelox: Retinal Detachments Are Visual Side Effects Of Oral Fluoroquinolones Antibiotics (7/22/13)
  • Current Use Of Cipro And Levaquin Associated With Increased Risk Of Detached Retina Eye Injury (4/4/12)
  • Current “First-Time” Users Of Avelox Who Received A Prescription In The Past 15 Days Had 3-Times Higher Rate Of Developing Uveitis, An Eyes / Vision Drug Side Effect (10/8/14)

In January 2016 Health Canada issued the latest drug safety alert concerning Avelox, Levaquin, and Cipro, this one having to do with a serious side effect concerning the eyes.

From this document “Summary Safety Review – Oral FLUOROQUINOLONES – Assessing the Potential Risk of Retinal Detachment”, we get these two primary points about the current situation:

  1. Health Canada’s follow-up safety review concluded that a link between the use of fluoroquinolones and the occurrence of retinal detachment cannot be ruled out at the present time.
  2. Given that retinal detachment is a medical emergency, the recommendations of the review were that the current labeling for oral fluoroquinolones be revised to highlight the urgency to see a health care professional if patients experienced vision problems during or following oral fluoroquinolone administration.

We will wait to see what label changes are made in Canada by the drug companies responsible for Avelox, Levaquin, and Cipro concerning this apparent retinal detachment side effect. And we will watch for any similar revisions to the Prescribing Information for these popular antibiotics here in the US.

[Read this article in full at original source]

_______________________________________________________________________________________

Free Avelox / Levaquin / Cipro

Case Evaluation

Strictly Confidential, No Obligation

_______________________________________________________________________________________

Fluoroquinolone Antibiotics Cipro, Avelox, And Levaquin Linked To Peripheral Neuropathy In First Large Epidemiologic Study

By

Neurology Medical Journal Article Reports Two-Times Increased Risk For This Nerve Damage Side Effect For New Users Of These Antibiotics

 
SUMMARY: The first large epidemiologic study has confirmed this link between Avelox, Cipro, and Levaquin with peripheral neuropathy. On August 22, 2014 the article, “Oral fluoroquinolone use and risk of peripheral neuropathy”, reporting about that study was published online before print by the medical journal Neurology.

The study was led by Dr. Mahyar Etminan, a drug safety researcher at the University of British Columbia. This study, which involved one million men, showed the current users of Cipro, Levaquin, and Avelox are approximately two-times more like to develop peripheral neuropathy than non-users. Significantly, this increased risk of developing peripheral neuropathy was similar across all the three of these brand name fluoroquinolone antibiotics.

We will continue to monitor this relatively unknown, still emerging drug safety issue and and report significant developments here.

[Read this article in full at original source]

_____________________________________________________________________

Levaquin / Cipro / Avelox
Free Case Evaluation

Strictly Confidential, No Obligation

______________________________________________________________________

Serious Nerve Damage Side Effect Peripheral Neuropathy Associated With Levaquin, Cipro, And Avelox May Be A Permanent Drug Injury

By

An August 2013 Label Change Mandated By The FDA For All Fluoroquinolone Antibiotics Was Intended To Raise The Profile Of This Relatively Unknown Risk

 
SUMMARY: In August 2013 the FDA determined that, although the risk of peripheral neuropathy has been described in the respective Package Insert, or label, of these fluoroquinolone antibiotic drugs since 2004, the (1) potential rapid onset and (2) risk of permanence aspects of this serious nerve damage side effect were not adequately described.

As pointed out the 2013 FDA Drug Safety Communication about Avelox, Cipro, and Levaquin,”These symptoms can occur early in treatment and may be permanent.”

We are investigating cases of peripheral neuropathy or serious nerve damage in patients who used Levaquin, Cipro, Avelox, or one of the other fluoroquinolone drugs as possible drug injury lawsuits against the responsible pharmaceutical company.

[Read this article in full at original source]

Our Other Websites

Drug Injury Watch

Drug Safety Developments

Lamb Law Office

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com